Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo- controlled trial. Lancet 2010; 376: 517 523. 58. Kalantar-Zadeh K, Abbott KC, Salahudeen AK et al. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005; 81: 543 554. 59. Pifer TB, McCullough KP, Port FK et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002; 62: 2238 2245. 60. Hoogeveen EK, Halbesma N, Rothman KJ et al. Obesity and mortality risk among younger dialysis patients. Clin J Am Soc Nephrol 2012; 7: 280 288. 61. World Health Organization. Prevention of Cardiovascular Disease: Guide- lines for Assessment and Management of Total Cardiovascular Risk. 2007. 62. Hooper L, Bartlett C, Davey Smith G et al. Systematic review of long term effects of advice to reduce dietary salt in adults. BMJ 2002; 325: 628. 63. Esnault VL, Ekhlas A, Delcroix C et al. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol 2005; 16: 474 481. 64. Phillips CO, Kashani A, Ko DK et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007; 167: 1930 1936. 65. Slagman MC, Waanders F, Hemmelder MH et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ 2011; 343: d4366. 66. Vogt L, Waanders F, Boomsma F et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19: 999 1007. 67. Ekinci EI, Clarke S, Thomas MC et al. Dietary salt intake and mortality in patients with type 2 diabetes. 